REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Millennium Management LLC

Millennium Management LLC increased its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 84.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 306,487 shares of the biotechnology company's stock after purchasing an additional 140,666 shares during the quarter. Millennium Management LLC owned 0.62% of REGENXBIO worth $3,586,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of RGNX. Redmile Group LLC raised its holdings in REGENXBIO by 21.0% in the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company's stock worth $95,901,000 after purchasing an additional 790,866 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of REGENXBIO by 258.7% during the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company's stock valued at $9,552,000 after acquiring an additional 588,773 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of REGENXBIO by 9.8% during the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company's stock valued at $102,756,000 after acquiring an additional 436,043 shares during the last quarter. Artal Group S.A. acquired a new position in shares of REGENXBIO during the first quarter valued at approximately $5,268,000. Finally, Integral Health Asset Management LLC raised its holdings in shares of REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after acquiring an additional 190,000 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

Wall Street Analysts Forecast Growth

RGNX has been the subject of a number of research analyst reports. Barclays reduced their target price on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, August 5th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Raymond James restated an "outperform" rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday. Finally, HC Wainwright restated a "buy" rating and issued a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, REGENXBIO presently has a consensus rating of "Moderate Buy" and an average price target of $35.45.

REGENXBIO Trading Up 3.1 %

REGENXBIO stock traded up $0.31 during mid-day trading on Monday, hitting $10.20. The company's stock had a trading volume of 423,079 shares, compared to its average volume of 602,255. The firm has a market capitalization of $502.41 million, a PE ratio of -1.73 and a beta of 1.21. REGENXBIO Inc. has a 1 year low of $9.11 and a 1 year high of $28.80. The stock's fifty day moving average is $11.46 and its two-hundred day moving average is $13.58.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business had revenue of $22.30 million during the quarter, compared to analyst estimates of $22.97 million. During the same period last year, the business posted ($1.66) earnings per share. The company's quarterly revenue was up 11.6% on a year-over-year basis. On average, equities analysts expect that REGENXBIO Inc. will post -4.66 EPS for the current fiscal year.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Kenneth T. Mills sold 2,210 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $13.77, for a total value of $30,431.70. Following the sale, the director now directly owns 408,035 shares in the company, valued at approximately $5,618,641.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,279 shares of company stock worth $864,034 over the last ninety days. Company insiders own 13.13% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.